

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001. Amended 01/01/11

Name of Entity:	Radiopharm Theranostics Limited (ASX: RAD)
ABN:	57 647 877 889

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Leila Alland
Date of Last Notice:	15 December 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or Indirect Interest	Direct														
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	-														
Date of change	13 Sep 2024														
No. of securities held prior to change	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>71,740</td><td>1,900,002</td></tr><tr><td>Indirect</td><td>-</td><td>-</td></tr><tr><td>Total</td><td>71,740</td><td>1,900,002</td></tr></table>				Shares	Options	Direct	71,740	1,900,002	Indirect	-	-	Total	71,740	1,900,002
	Shares	Options													
Direct	71,740	1,900,002													
Indirect	-	-													
Total	71,740	1,900,002													
Class	RAD ORDINARY FULLY PAID RADOA OPTION EXPIRING 24-AUG-2026														
Number acquired	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>1,000,000</td><td>500,000</td></tr><tr><td>Indirect</td><td>-</td><td>-</td></tr><tr><td>Total</td><td>1,000,000</td><td>500,000</td></tr></table>				Shares	Options	Direct	1,000,000	500,000	Indirect	-	-	Total	1,000,000	500,000
	Shares	Options													
Direct	1,000,000	500,000													
Indirect	-	-													
Total	1,000,000	500,000													
Number disposed	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>-</td><td>-</td></tr><tr><td>Indirect</td><td>-</td><td>-</td></tr><tr><td>Total</td><td>-</td><td>-</td></tr></table>				Shares	Options	Direct	-	-	Indirect	-	-	Total	-	-
	Shares	Options													
Direct	-	-													
Indirect	-	-													
Total	-	-													

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$0.04 per RAD ordinary share (with free attaching RADOA option per placement announced 25 Jun 2024)		
No. of securities held after change			
		Shares	Options
	Direct	1,071,740	2,400,002
	Indirect	-	-
	Total	1,071,740	2,400,002
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of placement shares and options approved by shareholders at the General Meeting held on 14 August 2024.		

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 – Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001. Amended 01/01/11

Name of Entity:	Radiopharm Theranostics Limited (ASX: RAD)
ABN:	57 647 877 889

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Riccardo Canevari
Date of Last Notice:	15 December 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or Indirect Interest	Direct and Indirect		
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Indirect interest held via broker nominee account		
Date of change	13 Sep 2024		
No. of securities held prior to change		Shares	Options
	Direct	8,503,584	29,824,013
	Indirect	1,150,000	-
	Total	9,653,584	29,824,013
Class	RAD ORDINARY FULLY PAID RADOA OPTION EXPIRING 24-AUG-2026 RADAN OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES		
Number acquired		Shares	Options
	Direct	(a) 3,750,000	(a) 1,875,000 (b) 24,000,000
	Indirect	-	-
	Total	3,750,000	25,875,000
Number disposed		Shares	Options
	Direct	-	-
	Indirect	-	-
	Total	-	-

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	(a) \$0.04 per RAD ordinary share (with free attaching RADOA option per placement announced 25 Jun 2024) (b) Incentive options approved by shareholders at General Meeting held 14 August 2024												
No. of securities held after change	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>12,253,584</td><td>55,699,013</td></tr><tr><td>Indirect</td><td>1,150,000</td><td>-</td></tr><tr><td>Total</td><td>13,403,584</td><td>55,699,013</td></tr></table>		Shares	Options	Direct	12,253,584	55,699,013	Indirect	1,150,000	-	Total	13,403,584	55,699,013
	Shares	Options											
Direct	12,253,584	55,699,013											
Indirect	1,150,000	-											
Total	13,403,584	55,699,013											
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	(a) Issue of placement shares and options approved by shareholders at the General Meeting held 14 August 2024. (b) Issue of incentive options approved by shareholders at General Meeting held 14 August 2024.												

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 – Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Radiopharm Theranostics Limited (ASX: RAD)
ABN	57 647 877 889

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Phillip Hains
Date of last notice	26 March 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect		
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Director related entities: The CFO Solution Team Pty Ltd Shared Office Services Pty Ltd		
Date of change	13 Sep 2024		
No. of securities held prior to change		Shares	Options
	Direct	-	1,900,002
	Indirect	6,256,632	2,083,560
	Total	6,256,632	3,983,562
Class	RAD ORDINARY FULLY PAID RADOA OPTION EXPIRING 24-AUG-2026		
Number acquired		Shares	Options
	Direct	-	-
	Indirect	9,700,000	4,850,000
	Total	9,700,000	4,850,000
Number disposed		Shares	Options
	Direct	-	-
	Indirect	-	-
	Total	-	-
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$0.04 per RAD ordinary share (with free attaching RADOA option per placement announced 25 Jun 2024)		

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

No. of securities held after change		Shares	Options
	Direct	-	1,900,002
	Indirect	15,956,632	6,933,560
	Total	15,956,632	8,833,562
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back		Issue of placement shares and options approved by shareholders at the General Meeting held on 14 August 2024.	

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺ closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001. Amended 01/01/11

Name of Entity:	Radiopharm Theranostics Limited (ASX: RAD)
ABN:	57 647 877 889

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Paul Hopper
Date of Last Notice:	7 December 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or Indirect Interest	Direct and Indirect														
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Director related entity														
Date of change	13 September 2024														
No. of securities held prior to change	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>400,000</td><td>-</td></tr><tr><td>Indirect</td><td>93,821,428</td><td>9,017,518</td></tr><tr><td>Total</td><td>94,221,428</td><td>9,017,518</td></tr></table>				Shares	Options	Direct	400,000	-	Indirect	93,821,428	9,017,518	Total	94,221,428	9,017,518
	Shares	Options													
Direct	400,000	-													
Indirect	93,821,428	9,017,518													
Total	94,221,428	9,017,518													
Class	RAD ordinary shares RADOA listed options														
Number acquired	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>55,000,000</td><td>27,500,000</td></tr><tr><td>Indirect</td><td>-</td><td>-</td></tr><tr><td>Total</td><td>55,000,000</td><td>27,500,000</td></tr></table>				Shares	Options	Direct	55,000,000	27,500,000	Indirect	-	-	Total	55,000,000	27,500,000
	Shares	Options													
Direct	55,000,000	27,500,000													
Indirect	-	-													
Total	55,000,000	27,500,000													
Number disposed	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>-</td><td>-</td></tr><tr><td>Indirect</td><td>-</td><td>-</td></tr><tr><td>Total</td><td>-</td><td>-</td></tr></table>				Shares	Options	Direct	-	-	Indirect	-	-	Total	-	-
	Shares	Options													
Direct	-	-													
Indirect	-	-													
Total	-	-													

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$0.04 per RAD ordinary share (with free attaching RADOA listed option per placement announced 25 Jun 2024)		
No. of securities held after change		Shares	Options
	Direct	55,400,000	27,500,000
	Indirect	93,821,428	9,017,518
	Total	149,221,428	36,517,518
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of placement shares and options approved by shareholders at the General Meeting held on 14 August 2024.		

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 – Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001. Amended 01/01/11

Name of Entity:	Radiopharm Theranostics Limited (ASX: RAD)
ABN:	57 647 877 889

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Hester Larkin
Date of Last Notice:	15 December 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or Indirect Interest	Direct and indirect														
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Held via broker nominee account														
Date of change	8 December 2023														
No. of securities held prior to change	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>-</td><td>1,900,002</td></tr><tr><td>Indirect</td><td>94,247</td><td>-</td></tr><tr><td>Total</td><td>94,247</td><td>1,900,002</td></tr></table>				Shares	Options	Direct	-	1,900,002	Indirect	94,247	-	Total	94,247	1,900,002
	Shares	Options													
Direct	-	1,900,002													
Indirect	94,247	-													
Total	94,247	1,900,002													
Class	RAD ORDINARY FULLY PAID RADOA OPTION EXPIRING 24-AUG-2026														
Number acquired	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>550,000</td><td>275,000</td></tr><tr><td>Indirect</td><td>-</td><td>-</td></tr><tr><td>Total</td><td>550,000</td><td>275,000</td></tr></table>				Shares	Options	Direct	550,000	275,000	Indirect	-	-	Total	550,000	275,000
	Shares	Options													
Direct	550,000	275,000													
Indirect	-	-													
Total	550,000	275,000													
Number disposed	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>-</td><td>-</td></tr><tr><td>Indirect</td><td>-</td><td>-</td></tr><tr><td>Total</td><td>-</td><td>-</td></tr></table>				Shares	Options	Direct	-	-	Indirect	-	-	Total	-	-
	Shares	Options													
Direct	-	-													
Indirect	-	-													
Total	-	-													

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$0.04 per RAD ordinary share (with free attaching RADOA option per placement announced 25 Jun 2024)														
No. of securities held after change	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>550,000</td><td>2,175,002</td></tr><tr><td>Indirect</td><td>94,247</td><td>-</td></tr><tr><td>Total</td><td>644,247</td><td>2,175,002</td></tr></table>				Shares	Options	Direct	550,000	2,175,002	Indirect	94,247	-	Total	644,247	2,175,002
	Shares	Options													
Direct	550,000	2,175,002													
Indirect	94,247	-													
Total	644,247	2,175,002													
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of placement shares and options approved by shareholders at the General Meeting held on 14 August 2024.														

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 – Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001. Amended 01/01/11

Name of Entity:	Radiopharm Theranostics Limited (ASX: RAD)
ABN:	57 647 877 889

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Ian Turner
Date of Last Notice:	15 December 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or Indirect Interest	Direct and indirect														
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Superannuation fund														
Date of change	13 September 2024														
No. of securities held prior to change	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>280,595</td><td>5,002,524</td></tr><tr><td>Indirect</td><td>590,833</td><td>70,422</td></tr><tr><td>Total</td><td>871,428</td><td>5,072,946</td></tr></table>				Shares	Options	Direct	280,595	5,002,524	Indirect	590,833	70,422	Total	871,428	5,072,946
	Shares	Options													
Direct	280,595	5,002,524													
Indirect	590,833	70,422													
Total	871,428	5,072,946													
Class	RAD ORDINARY FULLY PAID RADOA OPTION EXPIRING 24-AUG-2026														
Number acquired	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>2,250,000</td><td>1,125,000</td></tr><tr><td>Indirect</td><td>1,500,000</td><td>750,000</td></tr><tr><td>Total</td><td>3,750,000</td><td>1,875,000</td></tr></table>				Shares	Options	Direct	2,250,000	1,125,000	Indirect	1,500,000	750,000	Total	3,750,000	1,875,000
	Shares	Options													
Direct	2,250,000	1,125,000													
Indirect	1,500,000	750,000													
Total	3,750,000	1,875,000													
Number disposed	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>-</td><td>-</td></tr><tr><td>Indirect</td><td>-</td><td>-</td></tr><tr><td>Total</td><td>-</td><td>-</td></tr></table>				Shares	Options	Direct	-	-	Indirect	-	-	Total	-	-
	Shares	Options													
Direct	-	-													
Indirect	-	-													
Total	-	-													

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$0.04 per RAD ordinary share (with free attaching RADOA option per placement announced 25 Jun 2024)		
No. of securities held after change		Shares	Options
	Direct	2,530,595	6,127,524
	Indirect	2,090,833	820,422
	Total	4,621,428	6,947,946
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of placement shares and options approved by shareholders at the General Meeting held on 14 August 2024.		

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 – Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.